Published in PLoS One on September 15, 2016
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Primary biliary cirrhosis. N Engl J Med (2005) 7.59
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
Primary biliary cirrhosis. Hepatology (2009) 5.35
Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell (1995) 4.70
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med (2007) 2.91
Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol (1987) 2.90
The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity (2008) 2.81
Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum (2000) 2.61
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci (2008) 2.10
Dependence of self-tolerance on TRAF6-directed development of thymic stroma. Science (2005) 1.91
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut (2005) 1.91
High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum (2002) 1.44
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) (2001) 1.35
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet (2012) 1.32
Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity (2003) 1.24
LTbetaR signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen. J Immunol (2009) 1.24
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology (2014) 1.06
CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology (2010) 1.04
The diagnosis of primary biliary cirrhosis. Autoimmun Rev (2014) 1.03
Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Hepatology (2015) 1.02
Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells. J Autoimmun (2014) 1.02
High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol (2003) 1.02
The immune system, bone and RANKL. Arch Biochem Biophys (2014) 1.00
Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Rα(-/-) mice. J Autoimmun (2014) 1.00
Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol (2007) 0.99
Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology (2014) 0.98
The immunopathology of liver granulomas in primary biliary cirrhosis. J Autoimmun (2012) 0.98
Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis. Hepatology (2015) 0.93
Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis. J Autoimmun (2015) 0.90
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes Immun (2013) 0.90
Genetics and epigenetics of primary biliary cirrhosis. Semin Liver Dis (2014) 0.89
Natural killer cells regulate T cell immune responses in primary biliary cirrhosis. Hepatology (2015) 0.86
Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells. Clin Exp Immunol (2014) 0.86
DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. Clin Epigenetics (2015) 0.85
Unmet challenges in immune-mediated hepatobiliary diseases. Clin Rev Allergy Immunol (2015) 0.85
RANKL-RANK interaction in immune regulatory systems. World J Orthop (2012) 0.85
Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology (2011) 0.83
New therapies for primary biliary cirrhosis. Clin Rev Allergy Immunol (2015) 0.82
Women and primary biliary cirrhosis. Clin Rev Allergy Immunol (2015) 0.81
Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. Histopathology (2014) 0.81
Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis. Clin Exp Immunol (2015) 0.80
High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. J Bone Miner Metab (2009) 0.80
Geoepidemiology, Genetic and Environmental Risk Factors for PBC. Dig Dis (2015) 0.78
Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin Pharmacother (2014) 0.78
Expression of receptor activator of nuclear factor-kappa B ligand in leukocytes during acute kidney rejection after transplantation in rats. Transplant Proc (2013) 0.76
CCAAT/enhancer-binding protein β promotes receptor activator of nuclear factor-kappa-B ligand (RANKL) expression and osteoclast formation in the synovium in rheumatoid arthritis. Arthritis Res Ther (2015) 0.76
Alternative splicing generates a truncated isoform of human TNFRSF11A (RANK) with an altered capacity to activate NF-κB. Gene (2013) 0.76
Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma. J Cell Mol Med (2015) 0.78
Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clin Mol Hepatol (2016) 0.77
The epigenetics of PBC: The link between genetic susceptibility and environment. Clin Res Hepatol Gastroenterol (2016) 0.76
Common Variable Immunodeficiency and Liver Involvement. Clin Rev Allergy Immunol (2017) 0.75